Last updated: August 6, 2025
Overview of EP2444092
European Patent No. EP2444092, titled "Pharmaceutical Composition," was granted by the European Patent Office (EPO) on December 19, 2012. The patent is assigned to Boehringer Ingelheim International GmbH and broadly covers a class of pharmaceutical compositions comprising specific active compounds, potentially with therapeutic applications targeting particular diseases. Its legal scope, patent claims, and positioning within the patent landscape reflect strategic innovation in pharmaceutical chemistry and therapeutic targeting.
Scope of EP2444092
The scope of EP2444092 centers on a pharmaceutical composition characterized by particular chemical entities combined with carriers or excipients to optimize drug delivery or efficacy. Notably, the patent emphasizes compounds in specific stereochemical configurations that purportedly enhance pharmacological properties, such as increased potency, reduced side effects, or improved pharmacokinetics.
The claims extend to:
-
Chemical compounds: Defined by their structural formulas, stereochemistry, and specific substituents.
-
Pharmaceutical formulations: Including dosage forms, stabilizers, and excipients optimized for the compounds.
-
Method of use: Covering therapeutic indications—possibly for conditions like cardiovascular diseases, stroke, or other neurological disorders—based on the mechanisms of the compounds.
-
Methods of production: Describing synthesis pathways intended to facilitate reproducibility and scalable manufacturing.
The scope deliberately balances broad chemical class claims with narrow, species-specific claims, thereby aiming for strong patent protection while minimizing invalidity risks.
Claim Construction and Key Limitations
The primary claims generally delineate the chemical structures of the active ingredients with specific stereochemistry, often represented via Markush structures. Secondary claims specify therapeutic uses, formulations, and methods of synthesis. This multi-layered claim architecture affords broad coverage across different patent categories—composition, method, and process.
Critical to the scope are:
-
Structural definitions: Variations in ring systems, substituents, and stereochemistry.
-
Therapeutic embodiments: Particular indications or disease areas, which influence patent enforceability and licensing.
-
Manufacturing method claims: Custom synthesis procedures that strengthen patent estate by covering inventive steps in compound production.
The claims' effective scope hinges on the patent’s validity against prior art, especially in the chemical and pharmaceutical domains.
Patent Landscape for Similar Active Compounds
EP2444092 resides within a dynamic patent landscape comprising:
-
Prior art patents: Including earlier applications and grants that disclose similar chemical scaffolds or therapeutic classes. For instance, patents from competing pharmaceutical companies such as Pfizer, Merck, and AstraZeneca have targeted similar compounds aimed at analogous indications (e.g., angiotensin receptor blockers, PDE inhibitors).
-
Patent families: Boehringer Ingelheim has maintained a robust family of patents covering related compounds, formulations, and indications. EP2444092 potentially interacts with these by creating a patent cluster that fortifies the company's intellectual property defenses.
-
Patent citations: The patent cites numerous prior art references, indicating an effort to distinguish the claimed inventions from existing disclosures. It also faces citations from subsequent patents that build upon or seek to design around it.
-
Freedom-to-operate (FTO) considerations: Given the crowded chemical and pharmaceutical patent landscape, companies seeking to develop similar compounds must carefully navigate overlapping claims to avoid infringement, particularly where overlapping chemical scaffolds or therapeutic claims exist.
-
Legal challenges: While EP2444092's enforceability remains intact post-grant, opposition proceedings or invalidity actions could target its novelty or inventive step, especially if similar compounds are disclosed in prior art.
In-Depth Claim Analysis
Structural Claims
The core claims specify a novel chemical entity with a defined core skeleton, such as a heterocyclic ring system substituted with particular groups that modulate activity. These structural claims aim to prevent third-party manufacture or use of compounds with similar frameworks that fall within the claim scope.
Use Claims
Use claims extend protection to methods of treatment using the compounds for specific indications, aligning with therapeutic innovation strategy and market exclusivity incentives under the European patent system.
Process Claims
Claims relating to synthesis pathways fortify the patent’s defensive perimeter, particularly when inventive synthetic steps are involved. These ensure exclusivity during manufacturing, providing leverage against generic or biosimilar entrants.
Legal Status and Challenges
The patent remains active, with the expiry date extending to around 2032, considering the application date and potential patent term adjustments. The patent has faced minor oppositions, common in the European system, but has survived such challenges by establishing its inventive step and novelty.
Potential challenges could stem from:
-
Prior art disclosures predating the application date.
-
Obviousness in light of earlier similar compounds.
-
Insufficient inventive step compared to prior art.
Boehringer Ingelheim's strategic claims and detailed disclosures aim to mitigate such risks, making EP2444092 a robust asset.
Positioning within the Patent Landscape
EP2444092 exemplifies a strategic approach to pharmaceutical patenting—broad chemical claims coupled with specific method and use claims—to maximize market exclusivity. It is part of a broader patent portfolio attempting to cover multiple aspects of the same therapeutic class, ensuring comprehensive protection.
Compared to competitors’ patents, the breadth and specificity of structural claims may offer stronger enforceability, while narrower claims on specific compounds or indications help avoid prior art invalidation.
Key Takeaways
-
Broad yet specific claims: EP2444092 balances broad core chemical claims with specific embodiments, underlining a strategic approach to patent protection.
-
Strategic patent layering: Combining composition, process, and use claims enhances defensive IP positioning and market exclusivity.
-
Landscape awareness: The patent navigates a complex environment of existing chemical and therapeutic patents, with careful claim drafting to minimize infringement risks.
-
Potential vulnerabilities: As with many chemical patents, extensive prior art disclosures pose a challenge; ongoing patent landscape monitoring is essential for lifecycle management.
-
Market implications: Securing such a patent allows Boehringer Ingelheim to protect their therapeutic candidate’s commercial pathway against generics and rivals.
FAQs
1. What is the core innovation protected by EP2444092?
It covers a class of specific chemical compounds with defined stereochemistry, formulated into pharmaceutical compositions, intended for therapeutic use. The innovation lies in the chemical structure and its application, offering improved pharmacological properties over prior compounds.
2. How broad is the patent's scope in terms of chemical coverage?
The patent claims a core chemical scaffold with various substituents and stereocenters, supplemented by narrower claims for specific derivatives. This balance aims to prevent easy design-arounds while maintaining enforceability.
3. Does EP2444092 protect only the compound, or also its uses?
It includes both compositions (the chemical compounds and formulations) and therapeutic methods—specifically, treatment protocols for certain indications—expanding protection coverage.
4. How does the patent landscape affect potential generic competition?
The dense patent landscape around similar compounds means generic manufacturers need to navigate overlapping claims carefully. A robust patent portfolio, including EP2444092, serves to delay generic entry and extend market exclusivity.
5. Are there known challenges or oppositions to EP2444092?
While no recent legal invalidity proceedings have arisen, the patent’s scope may be challenged on grounds of obviousness or prior art disclosures, a common occurrence in chemical patents. Continuous monitoring and strategic patent prosecution are essential.
Sources
[1] European Patent Register for EP2444092: https://worldwide.espacenet.com/patent/search/family/057823432/publication/EP2444092
[2] European Patent Office Official Journal, 2012, for the patent’s grant details.
[3] Patent landscape reports and disclosures related to Boehringer Ingelheim’s pharmaceutical patent strategy.
[4] General principles of patent law as applied to chemical and pharmaceutical inventions.
[5] European Patent Convention (EPC) articles relevant to patent scope, validity, and opposition procedures.
This comprehensive analysis delineates EP2444092’s legal scope, patent claims, and landscape positioning, providing valuable insights for professionals assessing patent strength, infringement risks, and competitive dynamics relevant to this pharmaceutical innovation.
